Funding for this research was provided by:
AstraZeneca
Daiichi-Sankyo
Article History
Received: 4 March 2024
Accepted: 7 July 2024
First Online: 1 August 2024
Declarations
:
: Not applicable.
: University Hospital LMU Munich guidelines do not require individual consent for publication of images, as long as they are anonymized.
: J.D.: Speaker and/or consulting fees from AstraZeneca, Boehringer Ingelheim and Daiichi Sankyo, and participation in the ILD advisory committee for the DESTINY-Breast12 study for AstraZeneca and Daiichi Sankyo. N.K.: Speaker and/or consulting fees from AstraZeneca and Daiichi Sankyo, and participation in the ILD advisory committee for the DESTINY-Breast12 study for AstraZeneca and Daiichi Sankyo. P.T.: Research funds (to institution) and support attending meetings from AstraZeneca, and speaker and/or consulting fees from AstraZeneca, Daiichi Sankyo, Eli Lilly and Company, Genentech, Gilead, Novartis, and Roche.